Ball v. Baker

Background

Donald A. Ball filed a shareholder derivative action on behalf of Regeneron Pharmaceuticals, Inc. against Charles A. Baker and the other named individual defendants. Regeneron is the nominal defendant, meaning the company is the entity on whose behalf the derivative claims were brought. Ball originally filed the action in New York Supreme Court, and the defendants removed it to the U.S. District Court for the Southern District of New York under federal-question jurisdiction.

The complaint asserted New York fiduciary-duty claims. It alleged that the individual defendants approved or participated in a scheme involving charitable donations that allegedly covered Medicare beneficiaries’ copayments for Regeneron’s drug Eylea, in violation of the federal Anti-Kickback Statute and False Claims Act. Ball also alleged that several individual defendants sold Regeneron stock during the relevant period. The complaint relied extensively on a separate federal enforcement action brought by the United States against Regeneron in the District of Massachusetts.

Motions

Ball moved to remand, or return, the case to New York state court. He argued that his claims arose under New York law and did not present a federal question. The defendants opposed remand, arguing that the claims necessarily raised disputed and substantial questions under federal law.

The defendants also moved to dismiss for failure to state a claim or, alternatively, to stay the case until the related government action was resolved. Ball opposed a stay, arguing that the government action would not resolve or dispose of his derivative claims.

Court’s analysis

The court applied the four-part test for federal jurisdiction over a state-law claim that raises an important federal issue. The court concluded that the federal issues were necessarily raised because Ball’s fiduciary-duty claims depended on whether the alleged conduct violated the Anti-Kickback Statute and False Claims Act. The federal issues were also actually disputed because the alleged violations were central to both cases.

The court further found the federal issues substantial. It pointed to the federal Medicare program, related federal regulatory guidance, the need for uniform interpretation of federal law, and other lawsuits involving similar allegations against Regeneron. Finally, the court concluded that exercising federal jurisdiction would not improperly disrupt the balance between federal and state courts. Although New York law created the fiduciary-duty claims, the court found that the underlying dispute implicated substantial federal interests.

The court then applied factors concerning the parties’ interests, the courts’ interests, nonparties, and the public interest to the request for a stay. It found that both cases arose from the same core facts and that resolving the government action could substantially simplify this case. A stay would also reduce duplicative litigation and the risk of inconsistent rulings concerning the federal statutes. The court concluded that all of the relevant factors supported a stay.

Disposition

The court denied Ball’s motion to remand, stating in the conclusion that the denial was without prejudice. It granted the defendants’ motion to stay. All proceedings were stayed pending further order from the court, and the defendants were directed to notify the court within ten days after the government action was resolved. The defendants’ motions to dismiss were terminated without prejudice to renewal after the stay concluded. The court did not decide the merits of Ball’s fiduciary-duty claims or the defendants’ dismissal arguments.